Biocon shares surge as chairperson Kiran Mazumdar-Shaw reveals successor to Fortune India

Shares of Biocon  rose nearly 2% on Tuesday, bucking a weak broader market, after founder Kiran Mazumdar-Shaw in an exclusive interview with Fortune India revealed for the first time a structured succession plan for the biotechnology firm, naming her niece, Claire Mazumdar, as her successor.

Reacting to the development, the pharma stock gained by as much as 2.28% to ₹368.65 on the BSE. The company’s market capitalisation stood at ₹59,673 crore, with over 2 lakh shares changing hands over the counter, compared to the two-week average of 0.77 lakh shares.

The stock has seen a mixed performance trend. It hit a 52-week high of ₹424.95 on November 18, 2025, and a 52-week low of ₹317.90 on May 12, 2025. So far in calendar year 2026, the stock is down 6%, though it has gained nearly 3% over the past month. Over a six-month period, it has declined more than 5%, while delivering a return of nearly 9% over the past year.

In the interview, Mazumdar-Shaw outlined her succession plan as she prepares the four-decade-old group for its next phase of growth. Her to-be successor, Claire Mazumdar, is a 37-year-old biotech specialist and is founder-CEO of Bicara Therapeutics, a Nasdaq-listed firm incubated by Biocon.

While no formal timeline has been set for the transition, Claire is expected to take on a leadership role in the foreseeable future.

“I am the sole owner of Biocon, and I need to make sure that I put it in good hands. I have seen my niece Claire as my successor, because I think she has proved to me that she can run a company,” ,” Mazumdar-Shaw told Fortune India. 

Claire Mazumdar previously worked with Third Rock Ventures and Rheos Medicines before taking over as CEO of Bicara in 2018. The company went public on Nasdaq in 2024 at a valuation exceeding $800 million and now has a market capitalisation of over $1.6 billion, even as its lead cancer therapy targeting head and neck cancer remains in clinical trials. Biocon currently holds about a 10% stake in the company post-listing.

Last week, Biocon informed exchanges that the U.S. Food and Drug Administration (FDA) completed a pre-licence inspection (PLI) at its biosimilars facility in Biocon Park, Bengaluru, between April 20 and April 29, 2026. The inspection covered three biologics manufacturing units, five quality testing laboratories, and two warehouses.

At the end of the inspection, the FDA issued a Form 483 with five observations. The company said these were procedural in nature and did not relate to data integrity or quality oversight, with no repeat observations noted.

“The company will submit a comprehensive corrective and preventive action (CAPA) plan within the stipulated timeline and is confident all observations will be addressed fully and expeditiously,” Biocon said in a release.

Meanwhile, the company’s board is scheduled to meet on May 7 to consider investment in Biocon Biologics Ltd, its unlisted material subsidiary. The proposal involves acquisition of equity shares through a preferential allotment via private placement, including determination of the issue price, in line with Sebi regulations.

(DISCLAIMER: The views and opinions expressed by investment experts on fortuneindia.com are either their own or of their organisations, but not necessarily that of fortuneindia.com and its editorial team. Readers are advised to consult certified experts before taking investment decisions.)